A recent study found that enrollment in patient support programs was associated with greater adherence, improved persistence, and reduced medical and total healthcare costs for patients who were receiving adalimumab therapy.
Biologic drug developers often provide free-to-patient support programs (PSP) that assist patients with drug costs, injection training, or nurse support, but the impact of such programs for patients receiving adalimumab has not been assessed in the past. A recently published study sought to quantify the relationship between participation in a patient program and outcomes in patients who were initiating treatment with adalimumab.
The longitudinal, retrospective cohort study, funded by AbbVie (makers of the reference adalimumab, Humira), found that enrollment in patient support programs (PSP) was associated with greater adherence, improved persistence, and reduced medical and total healthcare costs for patients who were receiving adalimumab therapy.
The study used patient-level data derived from the Humira PSP and the Symphony Health Solutions’ administrative claims data for patients who initiated adalimumab treatment between January 2008 and June 2014. The enrolled patients were being treated for Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis, and all were naïve to biologic treatment before initiating adalimumab.
Of the 2386 patients included in the study, 1199 patients were in the PSP cohort and 1187 in the non-PSP cohort. All patients were required to have evidence of medical and pharmacy coverage from at least 6 months before and after their first adalimumab claim and at least 12 months after an index date (which was assigned as the earliest date of PSP enrollment. Time to enrollment following treatment initiation was used to assign index dates to the non-PSP cohort).
The researchers found the following:
The authors concluded that PSP enrollment was associated with greater adherence, improved persistence, and reduced medical and total healthcare costs for patients who were receiving adalimumab therapy. These findings are important, they say, because existing evidence shows rates of nonadherence to anti-tumor necrosis factor therapies exceeds 40%; nonadherence limits effectiveness, is associated with poor clinical outcomes, and creates a substantial economic burden. While no consistent risk factors for nonadherence have been identified, evidence suggests that support programs increase adherence to chronic therapy regimens.
The authors also suggest that their data provide support for prescribing physicians to encourage patients to enroll in PSPs, as well as for pharmaceutical companies to further develop and invest in such programs.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.